Fig. 1.

Liraglutide inhibits tumor progression through neutrophils. Measure blood cells in (A) LLC and (B) Hepa1‐6 cells bearing C57BL/6 mice using complete blood count. Concentrations of circulating (C) GM‐CSF, (D) VEGF‐A, (E) MMP‐9, (F) myeloperoxidase, and (G) elastase in mice were measured using ELISA. (H) Circulating dsDNA was purified and measured using an ultramicrospectrophotometer. Statistical significance was determined with t‐test. N = 6 mice for every group. Nonparametric tests were utilized to assess statistical significance between different treatment groups. *P < 0.05, **P < 0.01, ***P < 0.001. Error bars represent SD.